Oltan Amlo 40/5

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Oltan Amlo 40/5

Property Description
Active ingredients Amlodipine and Olmesartan Medoxomil
Form Fixed-Dose Combination (FDC) Oral Tablet
Pharmacological class Combination Antihypertensive Agents
Common use Management of Essential Hypertension (High Blood Pressure)
Origin Synthetic

What Type of Medicine is Oltan Amlo 40/5? (Identity and Classification)

Oltan Amlo 40/5 is a prescription-only, synthetic drug classified as a Combination Antihypertensive Agent for the treatment of essential hypertension. It is formulated as a Fixed-Dose Combination (FDC) oral tablet, integrating two distinct active ingredients into a single pill. The dual-component design is clinically recognized for its effectiveness in adults whose high blood pressure remains inadequately controlled by monotherapy, simplifying the regimen by combining two therapies.

Composition: A Dual-Action Combination of Active Ingredients

The preparation contains Olmesartan Medoxomil (an Angiotensin II Receptor Blocker or ARB) and Amlodipine (a Dihydropyridine Calcium Channel Blocker or CCB). The combination of these two distinct pharmacological classes is deliberately designed to provide complementary therapeutic effects. The Olmesartan component works by blocking signals that cause blood vessels to tighten, while the Amlodipine component acts directly on the vascular walls to induce relaxation.

How the Combination Provides Therapeutic Benefit

The primary purpose is the sustained reduction in blood pressure through a synergistic, dual-action mechanism. This action reduces peripheral vascular resistance, as combining these two agents is more effective at lowering blood pressure than using either drug alone, providing a comprehensive strategy for managing elevated arterial pressure.

Regulatory References

  1. NIH MedlinePlus
Advertisements

What side effects are possible with Oltan Amlo 40/5 ?

Possible side effects and safety information

The safety profile for Oltan Amlo 40/5 (Amlodipine/Olmesartan) is based on official regulatory classifications of adverse reactions observed in clinical study and post-marketing experience.

Frequency-Classified Adverse Reactions

The adverse reactions are grouped by the physiological system they affect and their frequency:

  • Common Reactions (occurring in 1% to 10% of patients): Peripheral edema (swelling), headache, and dizziness are frequently documented, often associated with the vascular and nervous systems. Fatigue is also classified as common.

  • Uncommon Reactions (occurring in 0.1% to 1% of patients): These include low blood pressure (hypotension), palpitations, and cough. Gastrointestinal effects such as diarrhea may also be uncommon.

Serious Adverse Reactions and Safety Constraints

Official labeling documents specific risks that are rare but clinically significant:

  • Fetal Toxicity: The Olmesartan component (an ARB) carries a risk of injury and death to the developing fetus and is contraindicated in the second and third trimesters of pregnancy.

  • Sprue-like Enteropathy: This is a rare, severe syndrome involving chronic diarrhea and weight loss, reported with long-term use of the Olmesartan component.

  • Cardiovascular Risk: Increased frequency, duration, or severity of angina or acute myocardial infarction is documented as a risk, particularly upon initiation or dose increase of the Amlodipine component in susceptible patients.

  • Contraindications: The medicine is restricted in patients with conditions such as severe hepatic impairment, severe renal impairment (creatinine clearance le 30 mL/min), or shock.

Contextual Safety Patterns

Some adverse events are noted to be time-related. For instance, symptomatic hypotension is possible at the start of treatment in volume- or salt-depleted patients. The serious condition, Sprue-like enteropathy, has been reported to manifest months to years after initiation. The safety profile also notes the risk of hyperkalaemia (elevated serum potassium) associated with the Olmesartan component.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section details only the officially documented clinical manifestations of overdose and the required emergency actions as stated in government regulatory sources for medicines containing Amlodipine and Olmesartan Medoxomil.


Documented Overdose Profile

Overdose Entity
Documented Manifestations The primary clinical sign is marked and prolonged systemic hypotension (severely low blood pressure) and excessive peripheral vasodilation. This may be accompanied by reflex tachycardia or, in some cases, bradycardia (slow heart rate).
Serious Outcomes Severe overdose may progress to cardiovascular shock with the potential for a fatal outcome if not treated immediately.
Antidote Status No specific antidote is known for the combination.

Required Emergency Action

Regulatory authorities mandate that immediate medical attention must be sought if an overdose is suspected or confirmed; emergency services must be contacted immediately. Management is strictly symptomatic and supportive treatment.

Procedural steps documented in official labeling include volume expansion (e.g., intravenous fluids) to treat hypotension, with the potential use of vasopressors if the hypotension is refractory. Due to the long-acting nature of Amlodipine, close clinical monitoring and extended observation in a hospital setting may be required, as both components are highly protein-bound and dialysis is not expected to be beneficial.

Advertisements

Therapeutic Uses of Oltan Amlo 40/5

What Oltan Amlo 40/5 Treats: Main Uses and Benefits

Oltan Amlo 40/5 is commonly used to help with Essential Hypertension, a chronic condition marked by sustained elevated blood pressure readings. It is relevant for adult patients who may require additional management when symptoms are difficult to control. It may be applied as an initial therapy for individuals with moderate or severe hypertension when supportive symptom management is appropriate.

The medication helps address symptom clusters related to systemic imbalance, such as symptoms of heightened physiological activity. Its key therapeutic benefit is its role in contributing to easing the risks associated with adverse cardiovascular events linked to conditions marked by increased physiological stress. The primary uses are for managing Essential Hypertension and helping with the risks associated with adverse cardiovascular events.

“This support may assist with managing goal-level pressure stability, which is often challenging with monotherapy.”

Quick Fact: Relief for Inadequately Controlled Pressure

The combination is considered relevant across therapeutic domains where long-term symptomatic support and pressure stabilization may be part of management.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Oltan Amlo 40/5 — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

  • Adults with essential hypertension.

Populations for whom use is contraindicated:

  • Patients with Hypersensitivity to Olmesartan, Amlodipine, dihydropyridine derivatives, or any excipients.
  • Females in the second and third trimesters of pregnancy; use must be discontinued as soon as possible when pregnancy is detected.
  • Patients with Severe Hepatic Insufficiency or Biliary Obstructive Disorders.
  • Patients with Severe Hypotension, Shock (including cardiogenic shock), or Obstruction of the Outflow Tract of the Left Ventricle (e.g., high-grade aortic stenosis).
  • Patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m^2) who are also taking Aliskiren.

Eligibility-related restrictions:

  • Age: Use is Not Recommended in patients below 18 years (safety/efficacy not established). Initial therapy is also Not Recommended in patients ge 75 years old.
  • Organ Function: Use is Not Recommended in Severe Renal Impairment (creatinine clearance <20 mL/min). Use requires Caution in Mild to Moderate Hepatic Impairment and Heart Failure.
  • Lactation: Use is Not Recommended for nursing mothers.

Connection to the overall eligibility profile: The regulatory documents establish who can and cannot use Oltan Amlo 40/5 by setting clear, required boundaries for patient eligibility. These boundaries include absolute prohibitions (contraindications) based on severe underlying conditions or pregnancy, as well as restrictions for specific populations defined by age and organ function status.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Oltan Amlo 40/5 is defined by specific regulatory restrictions and documented pharmacokinetic and pharmacodynamic effects from its two active ingredients.


Contraindicated and Restricted Combinations

Co-administration with Aliskiren is formally classified as contraindicated in patient populations with either diabetes mellitus or moderate to severe renal impairment due to the elevated risk of hyperkalemia and acute changes in renal function. A key restriction involves Simvastatin, for which the daily dose must be limited to 20 mg when combined with this medication, as the amlodipine component significantly increases the systemic exposure of Simvastatin.


Pharmacokinetic and Timing Requirements

The amlodipine component is affected by metabolic interference. Its systemic exposure is increased by strong CYP3A4 inhibitors and may be decreased by CYP3A4 inducers, including the herbal product St. John’s Wort. Furthermore, a mandatory timing separation rule applies to the olmesartan component: it must be administered at least 4 hours before Colesevelam hydrochloride to ensure proper systemic absorption.


Additive Pharmacodynamic Effects

Co-administration with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may result in a loss of the expected antihypertensive effect and an increased risk of renal impairment. Other documented interactions include an increased risk of hyperkalemia when combined with Potassium-sparing Diuretics or Potassium Supplements, and an increased risk of Lithium toxicity when co-used with Lithium.

Advertisements

Mechanism of Action

Oltan Amlo 40/5, a fixed-dose combination, exerts its action through two distinct pharmacologic domains, influencing both vascular tone and fluid balance.

Angiotensin II Receptor Blockade

One component, olmesartan, functions as a selective angiotensin II receptor blocker (ARB). It acts within the Renin-Angiotensin-Aldosterone System (RAAS) by binding to the angiotensin type 1 (AT1) receptors. This interaction prevents the potent signaling molecule, angiotensin II, from binding to its receptor. By blocking AT1 activation, olmesartan inhibits downstream cascades that typically promote vasoconstriction and the retention of sodium and water. This molecular sequence results in the systemic physiological consequence of decreased vascular resistance and plasma volume.


Modulation of Vascular Calcium Influx

The second component, amlodipine, is a dihydropyridine calcium channel blocker. Amlodipine modulates vascular smooth muscle pathways by inhibiting the influx of extracellular calcium ions through voltage-dependent L-type calcium channels on the cell membrane. This reduction in intracellular calcium limits the molecular steps required for arterial smooth muscle cell contraction. The resulting physiological effect is a change in arterial diameter, described as vasodilation.

Advertisements

Dosage and Administration Information

Oltan Amlo 40/5 is intended for oral administration as a fixed-dose combination (FDC) tablet for the chronic management of high blood pressure. The regimen is standardized to once-daily administration.


Administration and Dosing Schedule

  • Route and Frequency: The tablet is taken by mouth once per day.
  • Starting Dose: The usual starting dose for the combination is 5/20 mg (amlodipine/olmesartan medoxomil) once daily.
  • Titration: Any dose adjustment, if necessary, is recommended to occur in intervals of one to two weeks to allow the preceding dose to achieve its maximum therapeutic effect before escalation.
  • Maximum Dose: The highest approved dose is the 10/40 mg combination tablet once daily.

Intake Conditions and Population Constraints

The tablet can be administered with or without food, providing flexibility in daily use. It should be swallowed whole with a sufficient amount of fluid; official instructions do not advise crushing or chewing the tablet. The FDC may be used to replace the components taken separately or as initial therapy for patients likely to require multiple agents.

Specific usage constraints apply to certain populations. The FDC is not recommended for initial therapy in patients who are 75 years of age or older, or in patients with hepatic impairment. Caution is generally advised in the use of the medicine in patients with severe renal impairment.

Advertisements

Recent Clinical Evidence

Research Evidence for Oltan Amlo 40/5

Evidence for Use in Essential Hypertension Management

Research exploring this combination was evaluated in studies involving patients diagnosed with essential hypertension. The primary evidence base includes short-term, randomized, placebo-controlled trials. These studies examined outcomes related to systemic or functional imbalance, such as changes measured in seated systolic and diastolic blood pressure (SBP/DBP) over defined time intervals, typically lasting between 8 and 12 weeks.

Findings describe patterns observed in the studies where the combination preparation showed measurements that varied compared to trials of a placebo. Research so far contributes to the broader evidence landscape by describing short-term changes in blood pressure measurements. However, the follow-up durations were limited, meaning that data for sustained blood pressure control over multiple years are not fully established by these specific trials. The primary measurements examined were surrogate endpoints (blood pressure readings), and research does not determine whether an individual will respond similarly based only on these short-term group patterns.


Comparative Study Evidence and Special Populations

The combination was observed in studies focusing on patients whose high blood pressure remained inadequately controlled while taking only one of the component drugs alone. These comparative trials studies explored whether the dual-component therapy changed the likelihood of patients reaching predefined blood pressure targets. Findings describe patterns observed in the studies in patients where a single agent was observed to be insufficient.

Subgroup analyses was observed in some studies that included older adults and those with concomitant cardiovascular risk factors like diabetes. Research describes that the combination was evaluated in these individuals, and findings describe patterns observed similar to those found in the general study population. Data for certain groups, such as pediatric patients or those with severe organ impairments, remain insufficient.


Long-term Studies and Outcomes Research

Dedicated long-term studies focusing on this specific fixed combination for outcomes related to fatal and nonfatal cardiovascular events are limited. Instead, evidence contributes to the broader evidence landscape through reliance on large-scale trials of the component drug classes (Angiotensin II Receptor Blockers and Calcium Channel Blockers). Studies examined the correlation between blood pressure reduction and outcomes related to episodic or acute changes in cardiovascular health, drawing on data gathered from trials exploring the class effects. This evidence is limited and the generalizability is restricted to the populations studied in the original class trials.

While research has explored outcomes monitoring physiological strain or stress, the main evidence base relies on blood pressure as a surrogate endpoint, meaning the direct, specific demonstration of outcomes related to cardiovascular events for Oltan Amlo 40/5 is lacking. Comparative evidence is limited and focuses on comparisons against the single-agent components rather than all alternative dual or triple therapies.

Key Studies & References

  1. The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension (SEVITENSION study)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Oltan Amlo 40/5 (FAQ)

Q: Does it make you sleepy?

A: Official product information, based on clinical studies, reports drowsiness (somnolence), fatigue, and dizziness as possible effects. This indicates that some patients may experience a degree of reduced alertness. Patients should exercise caution when performing activities that require mental alertness until they know how the medicine affects them.

Q: Can I take it with alcohol?

A: Precaution is generally recommended if alcohol is consumed while taking this medicine. Regulatory information indicates that while some studies did not find significant changes with low blood alcohol levels, concurrent use with alcohol or other central nervous system depressants might cause further reductions in alertness and impair performance in sensitive individuals.

Q: Can children 2 years old use it?

A: Regulatory documents address the suitability for children based on age and formulation. Specifically, the official information states that some oral solution formulations are not recommended in children under 2 years old due to the amount of certain inactive ingredients (excipients). Additionally, film-coated tablets are typically not recommended for children under 6 years as they do not allow for accurate dose adjustment.

Q: What are the contraindications?

A: According to official regulatory product information, this medicine is contraindicated for people who have a known hypersensitivity (severe allergic reaction) to the active substance, its parent compound, related derivatives, or any of the ingredients in the formulation. It is also contraindicated for patients who have severe renal impairment, which is defined as a creatinine clearance less than 10 ml per minute.

Advertisements

How should Oltan Amlo 40/5 be stored and disposed of?

How to Store and Dispose of Oltan Amlo 40/5?

Oltan Amlo 40/5 (olmesartan medoxomil and amlodipine) must be stored strictly according to official regulatory conditions to maintain stability and safety.

Storage Requirements

The tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be kept in the closed container it was supplied in and protected from freezing, excess heat, moisture, and direct light.

Crucially, the medication must be stored out of the reach of children.

Storage Parameter Regulatory Requirement
Temperature Range Controlled room temperature
Environmental Protection Protect from freezing, heat, and moisture
Container Rule Store in original, tightly closed container

Disposal Instructions

Do not keep outdated or unused medicine. The official disposal protocol requires individuals to ask a healthcare professional, such as a pharmacist, for guidance on how to properly discard the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oltan Amlo 40/5  found in:

A-Z Index: